These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24050133)

  • 1. Modeling of human tumor xenografts and dose rationale in oncology.
    Simeoni M; De Nicolao G; Magni P; Rocchetti M; Poggesi I
    Drug Discov Today Technol; 2013 Sep; 10(3):e365-72. PubMed ID: 24050133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
    Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
    Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.
    Bernard A; Kimko H; Mital D; Poggesi I
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1057-69. PubMed ID: 22632710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
    LaCasse EC; Cherton-Horvat GG; Hewitt KE; Jerome LJ; Morris SJ; Kandimalla ER; Yu D; Wang H; Wang W; Zhang R; Agrawal S; Gillard JW; Durkin JP
    Clin Cancer Res; 2006 Sep; 12(17):5231-41. PubMed ID: 16951243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the active doses in humans from animal studies: a novel approach in oncology.
    Rocchetti M; Simeoni M; Pesenti E; De Nicolao G; Poggesi I
    Eur J Cancer; 2007 Aug; 43(12):1862-8. PubMed ID: 17604156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
    Bagley RG; Roth S; Kurtzberg LS; Rouleau C; Yao M; Crawford J; Krumbholz R; Lovett D; Schmid S; Teicher BA
    Int J Oncol; 2009 May; 34(5):1329-40. PubMed ID: 19360345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.
    Wartha K; Herting F; Hasmann M
    Pharmacol Ther; 2014 Jun; 142(3):351-61. PubMed ID: 24412280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered models have advantages over xenografts for preclinical studies.
    Becher OJ; Holland EC
    Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer.
    Decaudin D
    Anticancer Drugs; 2011 Oct; 22(9):827-41. PubMed ID: 21623183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
    Damia G; D'Incalci M
    Eur J Cancer; 2009 Nov; 45(16):2768-81. PubMed ID: 19762228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
    Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
    Wallqvist A; Huang R; Covell DG
    J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design, analysis and application of mouse clinical trials in oncology drug development.
    Guo S; Jiang X; Mao B; Li QX
    BMC Cancer; 2019 Jul; 19(1):718. PubMed ID: 31331301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.